European guidelines for primary antifungal prophylaxis in adult
haematology patients: summary of the updated recommendations
from the European Conference on Infections in Leukaemia

J 2018

European guidelines for primary antifungal prophylaxis in adult haematology patients: summary of the updated recommendations from the European Conference on Infections in Leukaemia

MAERTENS, J.A., C. GIRMENIA, R.J. BRÜGGEMANN, R.F. DUARTE, C.C. KIBBLER et. al.

Basic information

Original name

European guidelines for primary antifungal prophylaxis in adult haematology patients: summary of the updated recommendations from the European Conference on Infections in Leukaemia

Authors

MAERTENS, J.A. (56 Belgium, guarantor), C. GIRMENIA (380 Italy), R.J. BRÜGGEMANN (528 Netherlands), R.F. DUARTE (724 Spain), C.C. KIBBLER (826 United Kingdom of Great Britain and Northern Ireland), P. LJUNGMAN (752 Sweden), Zdeněk RÁČIL (203 Czech Republic, belonging to the institution), P. RIBAUD (250 France), M.A. SLAVIN (36 Australia), O.A. CORNELY (276 Germany), Peter J. DONNELLY (528 Netherlands) and C. CORDONNIER (250 France)

Edition

Journal of Antimicrobial Chemotherapy, Oxford, Oxford University Press, 2018, 0305-7453

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30104 Pharmacology and pharmacy

Country of publisher

United Kingdom of Great Britain and Northern Ireland

Confidentiality degree

není předmětem státního či obchodního tajemství

Impact factor

Impact factor: 5.113

RIV identification code

RIV/00216224:14110/18:00104699

Organization unit

Faculty of Medicine

DOI

http://dx.doi.org/10.1093/jac/dky286

UT WoS

000452916600002

Keywords in English

antifungal prophylaxis

Abstract

V originále

The European Conference on Infections in Leukaemia (ECIL) updated its guidelines on antifungal prophylaxis for adults using the grading system of IDSA. The guidelines were extended to provide recommendations for other haematological diseases besides AML and recipients of an allogeneic haematopoietic stem cell transplantation (HSCT). Posaconazole remains the drug of choice when the incidence of invasive mould diseases exceeds 8%. For patients undergoing remission-induction chemotherapy for AML and myelodysplastic syndrome (MDS), fluconazole can still offer an alternative provided it forms part of an integrated care strategy that includes screening with biomarkers and imaging. Similarly, aerosolized liposomal amphotericin B combined with fluconazole can be considered for patients at high risk of invasive mould diseases but other formulations of the polyene are discouraged. Fluconazole is still recommended as primary prophylaxis for patients at low risk of invasive mould diseases during the pre-engraftment phase of allogeneic HSCT whereas only a moderate recommendation could be made for itraconazole, posaconazole and voriconazole for patients at high risk. Posaconazole is strongly recommended for preventing invasive mould disease post-engraftment but only when graft-versus-host disease (GvHD) was accompanied by other risk factors such as its severity, use of an alternative donor or when unresponsive to standard corticosteroid therapy. The need for primary prophylaxis for other patient groups was less clear and should be defined by the estimated risk of invasive fungal disease (IFD).

Citovat

MAERTENS, J.A., C. GIRMENIA, R.J. BRÜGGEMANN, R.F. DUARTE, C.C. KIBBLER, P. LJUNGMAN, Zdeněk RÁČIL, P. RIBAUD, M.A. SLAVIN, O.A. CORNELY, Peter J. DONNELLY and C. CORDONNIER. European guidelines for primary antifungal prophylaxis in adult haematology patients: summary of the updated recommendations from the European Conference on Infections in Leukaemia. Journal of Antimicrobial Chemotherapy. Oxford: Oxford University Press, 2018, vol. 73, No 12, p. 3221-3230. ISSN 0305-7453. Available from: https://dx.doi.org/10.1093/jac/dky286.

@article{1473187,
   author = {Maertens, J.A. and Girmenia, C. and Brüggemann, R.J. and Duarte, R.F. and Kibbler, C.C. and Ljungman, P. and Ráčil, Zdeněk and Ribaud, P. and Slavin, M.A. and Cornely, O.A. and Donnelly, Peter J. and Cordonnier, C.},
   article_location = {Oxford},
   article_number = {12},
   doi = {http://dx.doi.org/10.1093/jac/dky286},
   keywords = {antifungal prophylaxis},
   language = {eng},
   issn = {0305-7453},
   journal = {Journal of Antimicrobial Chemotherapy},
   title = {European guidelines for primary antifungal prophylaxis in adult haematology patients: summary of the updated recommendations from the European Conference on Infections in Leukaemia},
   volume = {73},
   year = {2018}
}

TY  - JOUR
ID  - 1473187
AU  - Maertens, J.A. - Girmenia, C. - Brüggemann, R.J. - Duarte, R.F. - Kibbler, C.C. - Ljungman, P. - Ráčil, Zdeněk - Ribaud, P. - Slavin, M.A. - Cornely, O.A. - Donnelly, Peter J. - Cordonnier, C.
PY  - 2018
TI  - European guidelines for primary antifungal prophylaxis in adult haematology patients: summary of the updated recommendations from the European Conference on Infections in Leukaemia
JF  - Journal of Antimicrobial Chemotherapy
VL  - 73
IS  - 12
SP  - 3221-3230
EP  - 3221-3230
PB  - Oxford University Press
SN  - 03057453
KW  - antifungal prophylaxis
N2  - The European Conference on Infections in Leukaemia (ECIL) updated its guidelines on antifungal prophylaxis for adults using the grading system of IDSA. The guidelines were extended to provide recommendations for other haematological diseases besides AML and recipients of an allogeneic haematopoietic stem cell transplantation (HSCT). Posaconazole remains the drug of choice when the incidence of invasive mould diseases exceeds 8%. For patients undergoing remission-induction chemotherapy for AML and myelodysplastic syndrome (MDS), fluconazole can still offer an alternative provided it forms part of an integrated care strategy that includes screening with biomarkers and imaging. Similarly, aerosolized liposomal amphotericin B combined with fluconazole can be considered for patients at high risk of invasive mould diseases but other formulations of the polyene are discouraged. Fluconazole is still recommended as primary prophylaxis for patients at low risk of invasive mould diseases during the pre-engraftment phase of allogeneic HSCT whereas only a moderate recommendation could be made for itraconazole, posaconazole and voriconazole for patients at high risk. Posaconazole is strongly recommended for preventing invasive mould disease post-engraftment but only when graft-versus-host disease (GvHD) was accompanied by other risk factors such as its severity, use of an alternative donor or when unresponsive to standard corticosteroid therapy. The need for primary prophylaxis for other patient groups was less clear and should be defined by the estimated risk of invasive fungal disease (IFD).
ER  -

MAERTENS, J.A., C. GIRMENIA, R.J. BRÜGGEMANN, R.F. DUARTE, C.C. KIBBLER, P. LJUNGMAN, Zdeněk RÁČIL, P. RIBAUD, M.A. SLAVIN, O.A. CORNELY, Peter J. DONNELLY and C. CORDONNIER. European guidelines for primary antifungal prophylaxis in adult haematology patients: summary of the updated recommendations from the European Conference on Infections in Leukaemia. \textit{Journal of Antimicrobial Chemotherapy}. Oxford: Oxford University Press, 2018, vol.~73, No~12, p.~3221-3230. ISSN~0305-7453. Available from: https://dx.doi.org/10.1093/jac/dky286.

Detailed Information on Publication Record